Victory Capital Management Inc. decreased its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 59.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 115,932 shares of the company's stock after selling 168,512 shares during the period. Victory Capital Management Inc.'s holdings in Moderna were worth $4,820,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of MRNA. Wilmington Savings Fund Society FSB boosted its holdings in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc purchased a new position in shares of Moderna in the 4th quarter worth $37,000. Venturi Wealth Management LLC boosted its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after acquiring an additional 389 shares during the last quarter. Finally, Blue Trust Inc. increased its position in Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock valued at $47,000 after acquiring an additional 388 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.
Moderna Stock Down 1.1 %
MRNA stock traded down $0.36 during trading on Wednesday, hitting $33.45. The company had a trading volume of 3,530,087 shares, compared to its average volume of 6,551,956. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The company has a 50 day simple moving average of $35.51 and a 200-day simple moving average of $46.55. The firm has a market capitalization of $12.91 billion, a P/E ratio of -3.60 and a beta of 1.86.
Analyst Ratings Changes
A number of equities research analysts have issued reports on MRNA shares. UBS Group cut their price target on Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. Barclays lowered Moderna from an "overweight" rating to an "equal weight" rating and reduced their price objective for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Citigroup began coverage on Moderna in a research report on Thursday, March 13th. They set a "neutral" rating and a $40.00 target price on the stock. Finally, Argus cut Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $59.60.
Get Our Latest Stock Report on Moderna
About Moderna
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read More
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
